01- Novel DES Technology Promises to Become the Next DES Generation The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Read more HERE 02- The Fellow’s Corner | 3rd Clinical Case: True Bifurcation Lesion: Which Strategy Should We Use? Here is the third Fellow’s...
The number of people with post-COVID-19 syndrome seems to be growing exponentially, so we need long-term data to help physicians advise patients correctly. Among the many persistent symptoms, post-COVID-19 anosmia has good prognosis and almost full recovery at 1 year. In April, 2020, these same authors published a cohort of almost 100 COVID-19 positive patients (positive...
Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead to multiple problems; in addition, over time, cognitive deterioration will make complicated drug management schemes even more difficult for patients to handle. Aware of this problem, physicians often try to simplify schemes by discontinuing drugs, but what should...
Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration. This study looked into the cardio protection effect of betablockers (BB) after long term follow up in stable patients with no cardiac failure and a history...
12 weeks prior the ORBITA randomization, medical therapy optimization of all antianginal medication was achieved. Most importantly, optimization was well tolerated by all patients, with scarce adverse effects leading to therapy termination. In clinical practice, there is skepticism towards achieving maximal dosage with a cost-effective therapy, good tolerance, adherence, and no drug-drug interaction. The ORBITA...
Less than half of patients undergoing endovascular revascularization for peripheral artery disease to their lower limbs are discharged with optimal medical treatment. Their traditional risk factors are predictors of a more comprehensive treatment; however, women, patients with higher risk of thrombosis, and those more likely to lose a lower limb, are far from being treated...
01- Ticagrelor or Prasugrel in ST Elevation MI In patients undergoing ST elevation acute myocardial infarction (STEMI) receiving primary PCI, no significative differences between prasugrel and ticagrelor were found. However, the latter was associated to a significantly higher number of repeat MI when considered separately. Read more HERE 02- Number of Hours of Sleep and...
Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI or CABG). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce plaque regression and could eventually reduce the risk of coronary revascularization, especially complex revascularization. The FOURIER study randomized 27564 patients with stable CAD already on statins to evolocumab...
When operators decide to proceed with PCI despite a negative FFR (fairly frequent in the daily practice) outcomes at 5 years are far worse. This information comes from a large Canadian register presented at AHA 2020 Scientific Sessions, simultaneously published in JAMA. PCI to a non-ischemic lesion results in increased events risk at long term,...
Using only one compressed tablet or pill with a fixed combination of statins, angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics significantly lowered cardiovascular risk in a large population without previous events (primary prevention). However, it presented an intermediate risk of cardiovascular disease onset. The TIPS-3 (The International Polycap Study 3) study had a 2-by-2-by-2 factorial design,...